Findings

What do systematic reviews say?

344 questions · 346 findings · 97 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 31 · 9%GRADE not reported 6 · 1.7%Very low 154 · 44.5%Low 99 · 28.6%Moderate 39 · 11.3%High 17 · 4.9%

SPECIALISED TEAM vs usual care

Compliance with treatment ‐ treatment stopped in spite of need ‐ by two years · people with psychosis

SPECIALISED TEAM showed no clear difference in compliance with treatment ‐ treatment stopped in spite of need ‐ by… compared with STANDARD CARE (moderate certainty).

1 finding from 1 review

Early intervention for psychosis 2011 · Cochrane Headline outcomes only
RR 0.66 [0.29, 1.5]
1 study · 436 participants
Moderate

Beta‐blockers vs placebo

Leaving the study early · patients with schizophrenia

Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).

1 finding from 1 review

Beta‐blocker supplementation of standard drug treatment for schizophrenia 2001 · Cochrane Headline outcomes only
RR 1.62 [0.92, 2.83]
8 studies · 274 participants
Low

OFS vs no OFS

Overall survival: Median length of · women with early breast cancer

OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
HR 0.86 [0.78, 0.94]
11 studies · 10374 participants
High

OFS vs no OFS

Disease-free survival · women with early breast cancer

OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
HR 0.83 [0.77, 0.9]
10 studies · 8899 participants
High

OFS vs no OFS

Toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade" toxicity) · women with early breast cancer

OFS may leads to higher toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade"… compared with no OFS (low certainty).

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
RR 1.6 [1.41, 1.82]
6 studies · 5581 participants
Low

OFS vs no OFS

Toxicity ‐ mood · women with early breast cancer

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 5354 participants
Moderate

OFS vs no OFS

Toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) · women with early breast cancer

OFS may leads to higher toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) compared with no OFS (low certainty).

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
RR 1.66 [1.1, 2.5]
1 study · 2011 participants
Low

OFS vs no OFS

Contralateral breast cancer · women with early breast cancer

OFS probably leads to lower contralateral breast cancer compared with no OFS (moderate certainty).

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
RR 0.75 [0.57, 0.97]
8 studies · 7856 participants
Moderate

OFS vs no OFS

Quality of life · women with early breast cancer

1 finding from 1 review

Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 2996 participants
Low

Vaginal misoprostol vs placebo

Complete miscarriage · early fetal death (less than 24 weeks)

Vaginal misoprostol may leads to higher complete miscarriage compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 4.23 [3.01, 5.94]
5 studies · 305 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Nausea · early fetal death (less than 24 weeks)

Vaginal misoprostol may leads to higher nausea compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 21.85 [1.31, 364.37]
1 study · 154 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Diarrhoea · early fetal death (less than 24 weeks)

Vaginal misoprostol may leads to higher diarrhoea compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 40.85 [2.52, 662.57]
1 study · 154 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · early fetal death (less than 24 weeks)

Vaginal misoprostol may leads to higher pain relief compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.42
1 study · 154 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 0.67 [0.4, 1.11]
1 study · 45 participants
Low

Vaginal misoprostol vs placebo

Pelvic infection · early fetal death (less than 24 weeks)

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vaginal misoprostol vs placebo

Nausea · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in nausea compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.38 [0.43, 4.4]
2 studies · 88 participants
Low

Vaginal misoprostol vs placebo

Diarrhoea · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in diarrhoea compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 2.21 [0.35, 14.06]
2 studies · 88 participants
Low

Vaginal misoprostol vs placebo

Blood loss: haemoglobin difference > 10 g/L · early fetal death (less than 24 weeks)

It is very uncertain whether vaginal misoprostol changes blood loss: haemoglobin difference > 10 g/L compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.25 [0.38, 4.12]
1 study · 50 participants
Very low

Vaginal misoprostol vs placebo

Opiate use (as a proxy measure for pain) for all participants on ITT (including those without confirmed AMI) · early fetal death (less than 24 weeks)

It is very uncertain whether vaginal misoprostol changes pain (opiate use) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 5 [0.25, 101.11]
1 study · 84 participants
Very low

Vaginal misoprostol vs placebo

Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.17 [0.83, 1.64]
1 study · 32 participants
Low